Study finds women still get screwed on orgasms — and the blame doesn't just fall on men
If this was a newspaper and not a nice shiny website plugged into the wall with a few blue cables coming out the back, then there is only one headline we would use on this story: Come again?
Today we have new research out of the US where some academics have dedicated themselves to the burning question: Why aren't women having more orgasms?
Advertisement
Sadly, big tech, big pharma and big porn, despite being industries worth a combined $21 trillion, have failed to solve this.
Enter a new study that has some answers.
Published in the Journal of Social and Personal Relationships, this research has identified what is really going wrong in the bedroom — we are suffering from an Orgasm Pursuit Gap (OGP).
Straight men and women both prioritize the man orgasming — and that far less effort, on everyone's part, went into the woman achieving similar results, the study essentially found.
gpointstudio – stock.adobe.com
Advertisement
That is, how much perceived effort, both partners, put into a woman orgasming.
The study found that, essentially, straight men and women both prioritize the man getting there (sly wink) and that far less effort, on everyone's part, went into the woman achieving similar results.
Sigh. Great. Just great.
We (writing as a cis gender woman) are, statistically, paid less, do more housework and childcare, report higher rates of feeling rushed and pressed for time, and are more likely to die of stroke.
Advertisement
And now, it turns out that we are being even further short-changed in the bedroom.
Who do we ask for a refund?
The study was led by Carly Wolfer, a doctoral candidate in social psychology at City University of New York, who asked 127 people in heterosexual relationships aged 18-40-years-old to keep sex diaries for three weeks, a span which ultimately tracked 566 sexual events.
Advertisement
Ms Wolfer found that men orgasmed during 90 percent of their sexual encounters while women only got to the same place just over half the time, at 54 percent.
It gets worse.
Not only are men 15 times more likely to orgasm than women but when they do they have more satisfying orgasms.
(Programming note: I vehemently refuse to use the word 'climax'. We are not trapped in the early aughties badlands of mags doing stories like '15 ways to blow his mind'.)
That's 'not because it's 'just naturally harder' for women to orgasm — a common myth,' Wilder told the HuffPost, 'but because we put less effort into the sexual practices that support women's pleasure, like clitoral stimulation.'
Or to put it another way, heterosexual couples have a general tendency to do the things, positions, and upside-down, back-to-front, standing-on-your-head gymnastics that help men orgasm over what works for women.
Moreover, while this is going on, the research showed that both him and her are more focused on the guy orgasming, rather than the gal equally.
Wolfer found that men orgasmed during 90 percent of their sexual encounters while women only got to the same place just over half the time, at 54 percent.
Pixel-Shot – stock.adobe.com
Advertisement
Et voila, the orgasm pursuit gap.
As Wolfer explained to the HuffPost, the OGP is about 'how much someone wants an orgasm to happen — whether it's their own or their partner's — and how much effort they put into making it happen.'
From a feminist standpoint this all makes me want to grind my teeth and start emitting the sort of noises better suited to a pitbull chained up to a fence who is having a very bad day.
When it comes to female sexual enjoyment, the figures are a real turn off.
Advertisement
Last year the sex toy company Womanizer's We-Vibe sex and relationships study found that barely 40 percent of women across all age brackets are actually satisfied with the amount of sex they are having.
Meanwhile, an Australian study has previously found that only one in four women regularly masturbate, dealing a devastating blow to double AA battery sales.
Overall, researchers found that in the past year, nearly three quarters (72 percent) of men had masturbated but only just a bit more than one in three women (42 percent).
Advertisement
According to Womanizer's numbers, overall, 62 percent of women don't own a single sex toy.
So women of Australia it's time to unite: We are being shortchanged, and short changing ourselves, in the bedroom.
Forget budget deficits, we are massively stuck in a far more pressing orgasm deficit, strangely an issue that has not come up during this election cycle.
(Imagining Prime Minister Athony Albanese and Opposition Leader Peter Dutton even spluttering their way through saying the word 'orgasms' as they turned various shades of puce and became increasingly flustered is the best fun you can have with your pants on today.
Advertisement
No one should ever lie back and think of Canberra.)
The moral of all this: When it comes to your next sexual event, everyone needs to try.
Everyone needs to come to the party.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Buzz Feed
2 days ago
- Buzz Feed
Study Reveals The Biggest Risk Factors For Getting Early Dementia
Overall, the study results are consistent with what medical experts have been advising patients for years. Dr. Arman Fesharaki-Zadeh, an assistant professor of psychiatry and of neurology at the Yale School of Medicine, recommended three 'lifestyle measures' that folks may want to consider when trying to lower their risk of young-onset dementia ― starting with physical exercise. 'An active daily exercise practice can have far-reaching benefits, which include enhanced neurocognitive function,' Fesharaki-Zadeh said, adding that physical activity can boost neurogenesis (the formation of new neurons and synapses), vasculogenesis (the creation of new blood vessels) while also providing inherent mood benefits. Next, focus on eating nourishing foods. Fesharaki-Zadeh championed a Mediterranean-based diet, mentioning its well-documented benefits. 'Such dietary practice, which includes food groups such as green leafy vegetables, olive oil, salmon and blueberries, is rich in vitamins, omega-3 fatty acids, as well as antioxidants ― all neuroprotective factors,' he explained. Fesharaki-Zadeh recommended cognitive, mood and social stimulation to keep your mind sharp. For cognitive stimulation, this could look like learning a new language or attending a seminar, listening to music or dancing. Basically, anything that engages your mind will help it stay healthy. Mood stimulation, on the other hand, relates to stress reduction practices, 'such as mindfulness and yoga,' Fesharaki-Zadeh said. As for social stimulation, it's pretty simple: Try to connect with other humans face-to-face and actually talk to them as much as possible. 'In the era of pandemic and now post-pandemic, quality social connections should increasingly be encouraged and practiced,' Fesharaki-Zadeh said. While these habits don't cover the whole list of dementia risk factors, they are a pretty solid start. This article originally appeared on HuffPost.
Yahoo
3 days ago
- Yahoo
New Real-World Study by Columbia Data Analytics Confirms Semaglutide Significantly Reduces Kidney Disease Risk in Patients with Type 2 Diabetes
NEW YORK & ISTANBUL, June 16, 2025--(BUSINESS WIRE)--A groundbreaking study led by researchers from Columbia Data Analytics, Bogazici University and the City University of New York (CUNY) College of Technology, has demonstrated that semaglutide, a GLP-1 receptor agonist, significantly reduces the risk of major kidney disease events among patients with type 2 diabetes (T2D) and chronic kidney disease (CKD) in real-world clinical practice. Key findings: 26% Reduction in Major Kidney Events: Compared with standard care, semaglutide treatment was associated with a 26% reduction in the risk of major kidney disease events, including kidney failure and substantial loss of kidney function. This effect is consistent with, and slightly exceeds, the 24% risk reduction observed in the landmark FLOW clinical trial. Robust Real-World Evidence: Creating 896,257 external control arm semaglutide users and a comparator group from the Kythera Labs database (2019–2024), the study provides the largest real-world evaluation of semaglutide's renoprotective effects to date. Broad Patient Representation: The real-world cohort included a more diverse, representative patient population than typical clinical trials, enhancing the generalizability of the findings. Consistent Results Across Sensitivity Analyses: The study's conclusions remained robust across multiple sensitivity analyses, further supporting the reliability of the results. The researchers constructed an external control arm using real-world data and applied rigorous statistical methods, including propensity score matching and Cox regression, to ensure comparability with the FLOW trial population. The primary outcome was a composite of kidney failure onset and a sustained 50% reduction in estimated glomerular filtration rate. "These results provide compelling real-world evidence for the use of semaglutide in reducing the risk of kidney failure and progression in patients with type 2 diabetes and CKD," said lead author Dr. Onur Baser. "The findings support broader adoption of semaglutide as a renoprotective therapy and may inform clinical guidelines, payer coverage decisions, and health policy." Although reliance on diagnosis codes and the inability to confirm medication adherence are limitations typical of observational research, the large sample size, advanced statistical adjustments, and consistency with clinical trial data strengthen the findings' validity. About the Study Authors: Onur Baser, PhD (Bogazici University, City University of New York [CUNY] College of Technology) and Yuanqing Lu, MS (Columbia Data Analytics) Data Source: Kythera Labs, 2019–2024 Presented at: ISPOR 2025, Montréal, Québec, Canada Funding: No external funding Conflicts of Interest: None declared Citation: Baser O, Lu Y. External control arm with real world data to assess the effect of semaglutide on chronic kidney disease risk among patients with type 2 diabetes. Expert Opinion on Pharmacotherapy. Accepted June 6, 2025. View source version on Contacts Elizabeth Vivierlizv@
Yahoo
4 days ago
- Yahoo
New Real-World Study by Columbia Data Analytics Confirms Semaglutide Significantly Reduces Kidney Disease Risk in Patients with Type 2 Diabetes
NEW YORK & ISTANBUL, June 16, 2025--(BUSINESS WIRE)--A groundbreaking study led by researchers from Columbia Data Analytics, Bogazici University and the City University of New York (CUNY) College of Technology, has demonstrated that semaglutide, a GLP-1 receptor agonist, significantly reduces the risk of major kidney disease events among patients with type 2 diabetes (T2D) and chronic kidney disease (CKD) in real-world clinical practice. Key findings: 26% Reduction in Major Kidney Events: Compared with standard care, semaglutide treatment was associated with a 26% reduction in the risk of major kidney disease events, including kidney failure and substantial loss of kidney function. This effect is consistent with, and slightly exceeds, the 24% risk reduction observed in the landmark FLOW clinical trial. Robust Real-World Evidence: Creating 896,257 external control arm semaglutide users and a comparator group from the Kythera Labs database (2019–2024), the study provides the largest real-world evaluation of semaglutide's renoprotective effects to date. Broad Patient Representation: The real-world cohort included a more diverse, representative patient population than typical clinical trials, enhancing the generalizability of the findings. Consistent Results Across Sensitivity Analyses: The study's conclusions remained robust across multiple sensitivity analyses, further supporting the reliability of the results. The researchers constructed an external control arm using real-world data and applied rigorous statistical methods, including propensity score matching and Cox regression, to ensure comparability with the FLOW trial population. The primary outcome was a composite of kidney failure onset and a sustained 50% reduction in estimated glomerular filtration rate. "These results provide compelling real-world evidence for the use of semaglutide in reducing the risk of kidney failure and progression in patients with type 2 diabetes and CKD," said lead author Dr. Onur Baser. "The findings support broader adoption of semaglutide as a renoprotective therapy and may inform clinical guidelines, payer coverage decisions, and health policy." Although reliance on diagnosis codes and the inability to confirm medication adherence are limitations typical of observational research, the large sample size, advanced statistical adjustments, and consistency with clinical trial data strengthen the findings' validity. About the Study Authors: Onur Baser, PhD (Bogazici University, City University of New York [CUNY] College of Technology) and Yuanqing Lu, MS (Columbia Data Analytics) Data Source: Kythera Labs, 2019–2024 Presented at: ISPOR 2025, Montréal, Québec, Canada Funding: No external funding Conflicts of Interest: None declared Citation: Baser O, Lu Y. External control arm with real world data to assess the effect of semaglutide on chronic kidney disease risk among patients with type 2 diabetes. Expert Opinion on Pharmacotherapy. Accepted June 6, 2025. View source version on Contacts Elizabeth Vivierlizv@
